Safety, Efficacy, and Patient Preference for Subcutaneous Zilucoplan in Myasthenia Gravis After Switching from Intravenous Complement Component 5 Inhibitors: An Interim Analysis of a Phase 3b Study (P10-11.006)

To evaluate safety, efficacy, patient satisfaction and preference after switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) zilucoplan in adults with acetylcholine receptor autoantibody-positive (AChR Ab+) generalized myasthenia gravis (gMG).